JP2022536698A - 細胞老化活性化化合物 - Google Patents

細胞老化活性化化合物 Download PDF

Info

Publication number
JP2022536698A
JP2022536698A JP2021573470A JP2021573470A JP2022536698A JP 2022536698 A JP2022536698 A JP 2022536698A JP 2021573470 A JP2021573470 A JP 2021573470A JP 2021573470 A JP2021573470 A JP 2021573470A JP 2022536698 A JP2022536698 A JP 2022536698A
Authority
JP
Japan
Prior art keywords
compound
group selected
synthesis
guayuline
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536698A5 (https=
Inventor
サンタマリア，ザイラ タヴァレス
ヴァスケス，マリアーノ マルチネス
ヘレラ，ナディア ユディト ジャコボ
サバレタ，レティシア ロチャ
デヘサ，アレハンドロ ゼンテッラ
ガルシア，ベアトリス デル カルメン コウダー
Original Assignee
ウニベルシダー ナシオナル アウトノマ デ メキシコ
グユアール サン サルバドール ワイ プランタス デル デジェルト エスピーアール デ アールエル デ シーブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニベルシダー ナシオナル アウトノマ デ メキシコ, グユアール サン サルバドール ワイ プランタス デル デジェルト エスピーアール デ アールエル デ シーブイ filed Critical ウニベルシダー ナシオナル アウトノマ デ メキシコ
Publication of JP2022536698A publication Critical patent/JP2022536698A/ja
Publication of JP2022536698A5 publication Critical patent/JP2022536698A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
    • C07C59/82—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings the keto group being part of a ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
JP2021573470A 2019-06-10 2020-06-10 細胞老化活性化化合物 Pending JP2022536698A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MXMX/A/2019/006749 2019-06-10
MX2019006749A MX2019006749A (es) 2019-06-10 2019-06-10 Compuestos activadores de senescencia celular.
PCT/MX2020/050010 WO2020251346A1 (es) 2019-06-10 2020-06-10 Compuestos activadores de senescencia celular

Publications (2)

Publication Number Publication Date
JP2022536698A true JP2022536698A (ja) 2022-08-18
JP2022536698A5 JP2022536698A5 (https=) 2023-09-04

Family

ID=73781643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573470A Pending JP2022536698A (ja) 2019-06-10 2020-06-10 細胞老化活性化化合物

Country Status (5)

Country Link
US (1) US20220233553A1 (https=)
EP (1) EP3988521A4 (https=)
JP (1) JP2022536698A (https=)
MX (1) MX2019006749A (https=)
WO (1) WO2020251346A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133477A1 (en) * 2020-12-18 2022-06-23 Bridgestone Corporation Modified guayule resin product and related processes
BR112023015924A2 (pt) * 2021-02-08 2023-10-17 Bridgestone Corp Produto de resina de guaiule modificada, e, processo para preparar um produto de resina de guaiule modificada
GB2642547A (en) * 2024-07-12 2026-01-14 Univ Durham Compounds for use in senotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1809364B (zh) 2003-06-23 2010-06-16 杰龙公司 增加端粒酶活性的组合物和方法
CA2795981C (en) 2009-05-18 2017-06-27 Geron Corporation Compositions and methods for increasing telomerase activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, JPN6023041372, 2005, pages 1005 - 1008, ISSN: 0005341665 *
LIFE SCIENCES, vol. 77, JPN6023041371, 2005, pages 2855 - 2865, ISSN: 0005341666 *

Also Published As

Publication number Publication date
EP3988521A1 (en) 2022-04-27
WO2020251346A1 (es) 2020-12-17
MX2019006749A (es) 2022-11-28
US20220233553A1 (en) 2022-07-28
EP3988521A4 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
Wolfram et al. Homopiperazine-rhodamine B adducts of triterpenoic acids are strong mitocans
JP2022536698A (ja) 細胞老化活性化化合物
DE69302508T2 (de) Taxanderivate, ihre Herstellung und ihre Anwendung in der Onkologie
HU230128B1 (hu) Kiválasztott kondenzált pirrolokarbazolok
JP2009530405A (ja) 合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体
JP2012232997A (ja) シクロパミンアナログ及びその使用方法
DE69715010T2 (de) Ausgewählte k-252a derivate
JP2022502509A (ja) サルササポゲニン構造に基づく誘導体、医薬組成物及びその使用
Li et al. Facile and efficient access to Androsten-17-(1′, 3′, 4′)-pyrazoles and Androst-17β-(1′, 3′, 4′)-pyrazoles via Vilsmeier reagents, and their antiproliferative activity evaluation in vitro
Lee et al. Marliolide inhibits skin carcinogenesis by activating NRF2/ARE to induce heme oxygenase-1
D'yakonov et al. Catalytic cyclometallation in steroid chemistry V: Synthesis of hybrid molecules based on steroid oximes and (5Z, 9Z)-tetradeca-5, 9-dienedioic acid as potential anticancer agents
CN118001423A (zh) 亲水性抗Nectin-4抗体偶联药物及其制备方法和应用
Ge et al. New cinnamic acid-pregenolone hybrids as potential antiproliferative agents: Design, synthesis and biological evaluation
CN108853109A (zh) 迈华替尼组合物、相关化合物及其制备方法和用途
CN102311475A (zh) 一种从灵芝中分离出的新化合物及其制备方法和医药用途
JP2017504638A (ja) 重水素化キナゾリノン化合物及び該化合物を含む薬物組成物
Pettit et al. Antineoplastic agents. 606. The betulastatins
Denner et al. Isosteviol–A new scaffold for the synthesis of carbonic anhydrase II inhibitors
CA3190144A1 (en) Naphthalene monoimide compounds and methods thereof
CN107602518B (zh) 香豆素-二硫代氨基甲酸酯衍生物及其合成方法
JP2015506929A (ja) 神経保護剤及び抗炎症剤として作用するスピロステロイド系
EP1594886B1 (de) Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate
CN110734399A (zh) 一种查尔酮衍生物QNL-Chalcone的制备方法及应用
CN115160399B (zh) 一种皂皮酸类化合物及其制备方法和医用用途
CN115558013B (zh) 一种甾体磷酸酯化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240305

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240606